stockportfolio.pro
Labcorp Holdings Inc. (LH)
Healthcare · Diagnostics & Research · NYSE
Labcorp Holdings Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.55B | $10.31B | $11.33B | $11.55B | $13.98B | $13.14B | $14.88B | $12.16B | $13.01B | $13.95B |
| Gross profit | $2.85B | $3.09B | $3.18B | $3.25B | $4.95B | $4.99B | $3.71B | $3.36B | $3.62B | $4.01B |
| Net income | $711.80M | $1.23B | $883.70M | $823.80M | $1.56B | $2.38B | $1.28B | $418.00M | $746.00M | $876.50M |
| Net margin | 7.5% | 11.9% | 7.8% | 7.1% | 11.1% | 18.1% | 8.6% | 3.4% | 5.7% | 6.3% |
Source: Labcorp Holdings Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into LH stock?
At today's market cap of $22.24B, Labcorp Holdings Inc. is priced for free-cash-flow growth of about 6.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.21B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -7.2%/yr over the last five fiscal years and revenue 0%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Labcorp Holdings Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeLabcorp Holdings Inc. financial history by metric
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Labcorp Holdings Inc. — frequently asked questions
What is Labcorp Holdings Inc.'s revenue?
Labcorp Holdings Inc. (LH) reported revenue of $13.95B for fiscal year 2025, up 7.2% from the prior year, according to its SEC filings.
Is Labcorp Holdings Inc. profitable?
Yes. LH earned net income of $876.50M in fiscal 2025, a net margin of 6.3%.
What is LH's P/E ratio?
Labcorp Holdings Inc. trades at a price-to-earnings ratio of about 24.0 based on the latest data in our nightly-refreshed cache.
How fast is Labcorp Holdings Inc. growing?
LH's revenue grew at roughly -0.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Labcorp Holdings Inc. have?
As of fiscal year 2025, LH carried roughly $5.08B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Labcorp Holdings Inc.'s gross margin?
LH's gross margin was 28.8% in fiscal 2025 — gross profit of $4.01B on revenue of $13.95B.
What is Labcorp Holdings Inc.'s market cap?
Labcorp Holdings Inc. (LH) has a market capitalization of about $22.24B, based on the latest data in our nightly-refreshed cache.
When does Labcorp Holdings Inc.'s fiscal year end?
LH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into LH stock?
At today's market cap of $22.24B, Labcorp Holdings Inc. is priced for free-cash-flow growth of about 6.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.21B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -7.2%/yr over the last five fiscal years and revenue 0%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Labcorp Holdings Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.